Business

MARKET MOVERS

Dendreon expects slowdown in sales

istockphoto.com

Dendreon makes Provenge, which is designed to induce an immune response against prostate cancer.

Advertisement

Dendreon Corp. expects first-quarter sales to be slower than in the fourth quarter, when sales of its prostate cancer treatment Provenge were $77 million. The Seattle drug maker said first-quarter revenue growth for the drug would be in the low single digits. Fourth-quarter net income was $38.1 million, or 26 cents a share. Profit excluding some items was 45 cents a share. Analysts expected 60 cents.

Loading comments...
Real journalists. Real journalism. Subscribe to The Boston Globe today.
You're reading  1 of 5 free articles.
Get UNLIMITED access for only 99¢ per week Subscribe Now >
You're reading1 of 5 free articles.Keep scrolling to see more articles recomended for you Subscribe now
We hope you've enjoyed your 5 free articles.
Continue reading by subscribing to Globe.com for just 99¢.
 Already a member? Log in Home
Subscriber Log In

We hope you've enjoyed your 5 free articles'

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of BostonGlobe.com
Marketing image of BostonGlobe.com